title: Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.
abstract: Activating mutations within fibroblast growth factor receptor 3 (FGFR3), a receptor tyrosine kinase, are responsible for human skeletal dysplasias including achondroplasia and the neonatal lethal syndromes, Thanatophoric Dysplasia (TD) type I and II. Several of these same FGFR3 mutations have also been identified somatically in human cancers, including multiple myeloma, bladder carcinoma, and cervical cancer. Based on reports that strongly activated mutants of FGFR3 such as the TDII (K650E) mutant signal preferentially from within the secretory pathway, the inhibitory properties of nordihydroguaiartic acid (NDGA), which blocks protein transport through the Golgi, were investigated. NDGA was able to inhibit FGFR3 autophosphorylation both in vitro and in vivo. In addition, signaling molecules downstream of FGFR3 activation such as signal transducers and activators of transcription (STAT)1, STAT3, and mitogen-activated protein kinase (MAPK) were inhibited by NDGA treatment. Using HEK293 cells expressing activated FGFR3-TDII, together with several multiple myeloma cell lines expressing activated forms of FGFR3, NDGA generally resulted in a decrease in MAPK activation by 1 hour, and resulted in increased apoptosis over 24 hours. The effects of NDGA on activated FGFR3 derivatives targeted either to the plasma membrane or the cytoplasm were also examined. These results suggest that inhibitory small molecules such as NDGA that target a specific subcellular compartment may be beneficial in the inhibition of activated receptors such as FGFR3 that signal from the same compartment.
authors.affiliation: Department of Chemistry and Biochemistry, Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California 92093-0367, USA.
authors.forename: April N
authors.initials: AN
authors.lastname: Meyer
authors.forename: Christopher W
authors.initials: CW
authors.lastname: McAndrew
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Donoghue
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D006056:Golgi Apparatus / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006918:Hydroxyurea / Q000031:analogs & derivatives / Q000494:pharmacology; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D009637:Masoprocol / Q000494:pharmacology*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D010766:Phosphorylation / Q000187:drug effects; D051498:Receptor, Fibroblast Growth Factor, Type 3 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013796:Thanatophoric Dysplasia / Q000201:enzymology / Q000235:genetics; D014162:Transfection
chemical_list: D016859:Lipoxygenase Inhibitors; D016222:Fibroblast Growth Factor 2; D009637:Masoprocol; D051498:Receptor, Fibroblast Growth Factor, Type 3; C063449:zileuton; D006918:Hydroxyurea
references.citation: J Mol Biol. 2006 Mar 31;357(3):783-92
references.pmid: 16476447
references.citation: Hum Mol Genet. 1996 Apr;5(4):509-12
references.pmid: 8845844
references.citation: Biochem Biophys Res Commun. 2003 Feb 21;301(4):927-33
references.pmid: 12589801
references.citation: J Cell Biochem. 2007 Dec 15;102(6):1529-41
references.pmid: 17486636
references.citation: Mol Cell Biol. 1996 Aug;16(8):4081-7
references.pmid: 8754806
references.citation: Cell Death Differ. 1998 Oct;5(10):894-900
references.pmid: 10203695
references.citation: Appl Biochem Biotechnol. 2002 Jul-Dec;102-103(1-6):239-50
references.pmid: 12396127
references.citation: J Biochem Mol Biol. 2002 Sep 30;35(5):518-23
references.pmid: 12359096
references.citation: Nat Genet. 1995 Mar;9(3):321-8
references.pmid: 7773297
references.citation: J Biochem. 1996 May;119(5):863-9
references.pmid: 8797085
references.citation: Blood. 1997 Nov 15;90(10):4062-70
references.pmid: 9354676
references.citation: Science. 2002 Dec 6;298(5600):1912-34
references.pmid: 12471243
references.citation: Mol Biol Cell. 2001 Apr;12(4):931-42
references.pmid: 11294897
references.citation: Ann Oncol. 2000;11 Suppl 1:131-5
references.pmid: 10707795
references.citation: BJU Int. 2008 Feb;101(4):436-9
references.pmid: 18234062
references.citation: J Biol Chem. 1998 Jan 30;273(5):3068-75
references.pmid: 9446623
references.citation: Oncogene. 2001 Jul 19;20(32):4416-8
references.pmid: 11466624
references.citation: J Biol Chem. 2004 Oct 8;279(41):43254-60
references.pmid: 15292251
references.citation: Curr Pharm Biotechnol. 2002 Sep;3(3):275-83
references.pmid: 12164482
references.citation: Cytokine Growth Factor Rev. 2005 Apr;16(2):233-47
references.pmid: 15863038
references.citation: J Biol Chem. 1994 Mar 18;269(11):8260-7
references.pmid: 7510683
references.citation: Cancer Res. 2001 Feb 15;61(4):1265-8
references.pmid: 11245416
references.citation: J Cell Biochem. 2004 Apr 1;91(5):973-86
references.pmid: 15034932
references.citation: Proc Natl Acad Sci U S A. 1996 May 28;93(11):5241-6
references.pmid: 8643560
references.citation: Prostaglandins Leukot Med. 1984 Jan;13(1):53-60
references.pmid: 6424136
references.citation: Curr Biol. 1995 May 1;5(5):500-7
references.pmid: 7583099
references.citation: Toxicol Appl Pharmacol. 2006 Aug 1;214(3):230-6
references.pmid: 16473382
references.citation: Front Biosci. 2005 May 01;10:1961-76
references.pmid: 15769677
references.citation: Int J Immunopharmacol. 1997 May;19(5):263-75
references.pmid: 9439765
references.citation: Nat Genet. 1999 Sep;23(1):18-20
references.pmid: 10471491
references.citation: Biochem Biophys Res Commun. 2002 Aug 30;296(4):942-8
references.pmid: 12200139
references.citation: J Pharmacol Exp Ther. 1991 Mar;256(3):929-37
references.pmid: 1848634
references.citation: J Cell Sci. 1998 Apr;111 ( Pt 7):951-65
references.pmid: 9490639
references.citation: Clin Cancer Res. 2002 Apr;8(4):945-54
references.pmid: 11948098
references.citation: Biochim Biophys Acta. 1992 Jun 10;1135(2):185-99
references.pmid: 1319744
references.citation: Cytokine Growth Factor Rev. 2005 Apr;16(2):205-13
references.pmid: 15863035
references.citation: Breast Cancer Res Treat. 2005 Nov;94(1):37-46
references.pmid: 16142439
references.citation: Inflammation. 1984 Jun;8(2):143-55
references.pmid: 6430801
references.citation: Am J Hum Genet. 1999 Mar;64(3):722-31
references.pmid: 10053006
references.citation: Biochem Biophys Res Commun. 1998 Dec 30;253(3):869-76
references.pmid: 9918822
references.citation: Adv Cancer Res. 1993;60:1-41
references.pmid: 8417497
references.citation: Endocr Rev. 2005 Feb;26(1):63-77
references.pmid: 15689573
references.citation: J Biol Chem. 2003 May 9;278(19):17344-9
references.pmid: 12624096
references.citation: J Cell Biochem. 2008 Feb 1;103(2):624-35
references.pmid: 17562544
references.citation: Nat Genet. 1997 Jul;16(3):260-4
references.pmid: 9207791
references.citation: Endothelium. 2001;8(2):117-35
references.pmid: 11577705
references.citation: Bioorg Med Chem Lett. 2007 Jul 15;17(14):4026-9
references.pmid: 17502145
references.citation: Oncogene. 2000 Jul 6;19(29):3309-20
references.pmid: 10918587
references.citation: Cancer Sci. 2007 Sep;98(9):1417-23
references.pmid: 17645780
references.citation: Mol Cell Biol. 1997 Oct;17(10):5739-47
references.pmid: 9315632
references.citation: Biochemistry. 2000 Dec 26;39(51):15705-12
references.pmid: 11123895
references.citation: Trends Genet. 2000 Jun;16(6):265-71
references.pmid: 10827454